Yayın:
Cell death-based pharmacodynamic biomarkers (M30 and M65): The pros and cons

Basit Görünüm
dc.contributor.authorUlukaya, Engin
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentBiyokimya Bölümü
dc.contributor.orcid0000-0003-4875-5472
dc.contributor.researcheridK-5792-2018
dc.date.accessioned2024-08-08T05:09:24Z
dc.date.available2024-08-08T05:09:24Z
dc.date.issued2015-08-01
dc.identifier.endpageE6
dc.identifier.issn0959-4973
dc.identifier.startpageE5
dc.identifier.uri1473-5741
dc.identifier.urihttps://hdl.handle.net/11452/43782
dc.identifier.volume26
dc.identifier.wos000431624200011
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.journalAnti-cancer Drugs
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOncology
dc.subjectPharmacology & pharmacy
dc.subjectOncology
dc.subjectPharmacology & pharmacy
dc.titleCell death-based pharmacodynamic biomarkers (M30 and M65): The pros and cons
dc.typeOther
dc.type.subtypeMeeting Abstract
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Biyokimya Bölümü
local.indexed.atWOS

Dosyalar

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications